EU GMP is the entry ticket, not the business case

Nov 19, 2026 · @Wilson B

The prize is real. So is the bill.

Canada shipped about 276 tonnes of medical cannabis flower overseas in 2025. Add extracts and Statistics Canada puts the value at CA$643m, roughly £342m (MJBizDaily).

The UK is now a real part of that story. Home Office figures reported by Business of Cannabis show UK flower imports doubled to 30,062kg in 2025. Of that, 17,067kg came straight from Canada. The year before, the direct Canadian figure was 2,578kg.

Every one of those kilos had to arrive with a valid GMP certificate behind it. That is why "get EU GMP" now sits at the top of so many Canadian board packs.

I have spent most of my career in pharmaceutical quality and validation, and the last several years in medical cannabis. My view is simple. EU GMP gets you into the room. It does not win you the business.

If you run a Canadian site, you probably know the standard better than most UK buyers do. What tends to be missing is a clear view of the other end. Who actually holds the permissions in the UK? Why does a first shipment take so long? And why is the certificate you worked so hard for only one line in somebody else's file?

So this covers both ends: what the standard asks for, what it costs in £ and CA$, how the UK route really works, and what I would check before spending anything.

Conversions use £1 = CA$1.88 and €1 = £0.835 (mid November 2026 mid market rates). Figures are rounded.

What EU GMP actually is

EU GMP is the pharmaceutical manufacturing standard set out in EudraLex Volume 4. Part I covers finished medicines, Part II covers active substances, and the annexes deal with specific product types. For cannabis flower, Annex 7 on herbal medicinal products is the one to read first, alongside Chapter 1 on the pharmaceutical quality system.

Three points get lost in most sales decks.

  1. Nobody in Brussels hands out the certificate. The national authority of an EU member state inspects your site and issues it, and the result is logged on the EudraGMDP database. Canopy Growth's Kincardine site, for example, was certified by a German regional health inspectorate (Benzinga). The inspection is normally tied to an EU importer who holds a manufacturing and import authorisation (MFLRC).
  2. Canadian GPP is not GMP. Good Production Practices under the Cannabis Regulations are the domestic baseline. A Drug Establishment Licence with Health Canada GMP puts you further ahead, but EU inspectors still audit the site themselves. The usual gaps are process validation, stability programmes, equipment qualification and a quality system that can stand up to a medicines inspector (MJBizDaily).
  3. There are two ways in. You host an inspection and hold your own certificate. Or you grow to GACP, ship to a licensed EU site, and let that site carry out the GMP steps and the Qualified Person release. The second route is cheaper up front and, as the next section shows, getting harder to rely on.

One more cost that catches people out. For product going into the EU, each batch is retested on arrival by a GMP certified European lab, because the Canada and EU mutual recognition arrangements do not extend to cannabis (MFLRC).

Where GPP stops and EU GMP starts

The gap between the two standards is mostly about proof. GPP asks you to make clean, safe, traceable cannabis. EU GMP asks you to prove, on paper and in data, that you will make the same product every time.

AreaCanadian GPPEU GMPWhat you have to close
RulebookPart 5 of the Cannabis RegulationsEudraLex Volume 4, with Annex 7 for herbal productsA different standard, read by a different inspector
Who inspectsHealth CanadaAn EU national authority, at your siteYou host a foreign medicines inspection
Batch releaseQuality Assurance Person approves the lotQualified Person certifies each batch for EU releaseYour batch record must satisfy someone else's QP
Quality systemSOPs and a written GPP programme with recordsFull pharmaceutical quality system: change control, deviations, CAPA, product reviewsUsually the largest piece of work, and mostly people and paper
Process validationNot explicitly requiredMandatory, with protocols and reportsShow that drying, trimming and packing give the same result every run
Equipment and softwareNot specifiedQualified equipment and validated computerised systemsIQ, OQ and PQ on critical kit, plus your tracking software
EnvironmentSanitary premises with ventilation and filtrationContinuous monitoring with alert and action limits, classified rooms where neededHVAC and monitoring upgrades, the main capital cost
StabilityNot requiredRequired, to ICH guidelinesStart early, because it runs on calendar time

Sources: GrowerIQ and MFLRC. The last column is my reading of what each difference means on the ground.

Look at how little of that table is about the building. Operators tend to budget for HVAC and cleanrooms and then get caught out by documents, data and habits. An inspector will assume the rooms are clean. What gets tested is whether your records hold up and whether your team can explain why they do what they do.

The line between GACP and GMP is moving

For years the European model rested on a split. Grow and dry under GACP in Canada, then finish, test and release under GMP in Portugal, Spain or Germany. Two changes have put that under pressure.

The GACP guideline was rewritten. The EMA adopted Revision 1 of its Good Agricultural and Collection Practice guideline in July 2025, the first update since 2006. It now deals with indoor cultivation directly and ties GACP explicitly to GMP Part II and Annex 7 (ECA Academy). The message is that quality starts in the grow room, not at the factory door.

A German authority drew the line at drying. On 8 June 2026 the Hessian State Office for Health and Care published guidance treating controlled drying of flower as a critical manufacturing step under EU GMP. It also treats irradiation and similar decontamination as reprocessing that belongs inside a validated process, and asks import applications to show which site and which standard covered each step (MFLRC).

That guidance is one state's interpretation, not a new law, and I would not overstate it. But the direction is clear. If drying has to sit inside GMP, the certificate has to sit with whoever dries the flower. For most Canadian exporters that means the GMP boundary moves back to their own drying rooms.

Selling through an EU processing partner while you work towards your own certificate still makes sense as a bridge. The revenue helps fund the project and the relationships carry over. I would just not build a long term plan on it.

What it costs and how long it takes

For an existing Canadian site, plan on 12 to 24 months and anything from about £418k (CA$785k) to several million in facility upgrades, systems and documentation (MFLRC). Where you land in that range depends on how far the site sits from the standard today.

A new build is a different order of money. GrowerIQ puts it at about £2.1m to £9.2m (CA$3.9m to CA$17.3m) over 18 to 36 months, converted from euros.

PhaseTypical timelineEstimate in £Estimate in CA$
Building the facility6 to 18 months£1.7m to £8.4m+CA$3.1m to CA$15.7m+
Quality system6 to 12 months£167k to £418kCA$314k to CA$785k
Validation and stability studies6 to 12 months£125k to £334kCA$236k to CA$628k
Application and inspection3 to 12 months£42k to £125kCA$79k to CA$236k
Total, new build18 to 36 months£2.1m to £9.2m+CA$3.9m to CA$17.3m+

Other published figures for compliant construction and validation alone start lower, at about £710k to £1.7m (CA$1.3m to CA$3.1m) (Highly Capitalized). The honest answer is that it depends on the state of your site, which is why the gap assessment comes first.

On time, 18 to 24 months is a fair planning figure for a working Canadian site (Elevated Signals). You can throw money at construction. You cannot throw money at stability data, or at an inspector's diary. Authorities inspect worldwide with small teams, and a missed slot can cost you months.

Then there is the cost nobody puts on the slide. Once certified you carry higher lab fees and a bigger quality team every year, as one certified Ontario producer has described. Certificates typically run for about 3 years before reinspection, so this is a permanent step up in overhead, not a project cost.

The UK is not Germany

Most Canadian export plans are written for Germany and assume the UK works the same way. It does not, and the difference explains most of the frustration Canadian producers describe: a certified site, a willing buyer, and still months before anything moves.

Almost all medical cannabis prescribed in the UK is an unlicensed medicine, known as a "special". Only Sativex and Epidyolex hold marketing authorisations (Hill Dickinson). That changes who does what.

The licences sit with your UK importer, not with you. They need:

  • A Home Office controlled drugs domestic licence, plus an import licence for every shipment. The import licence fee is £24 (about CA$45), with a service standard of around 7 working days (WTO import licensing notification).
  • An MHRA licence. For product arriving from outside the EEA, such as Canada, that is a Manufacturer's (Specials) Licence. For product from an EEA state it is a Wholesale Dealer's Licence (Hill Dickinson).

The MHRA wants your GMP certificate with each import notification. Its guidance on unlicensed cannabis based products asks for a valid GMP certificate for the site of manufacture, and the product cannot be imported if the MHRA objects within 28 days of acknowledging the notification.

There is no Qualified Person certification step for specials. Under a Manufacturer's (Specials) Licence, release is by the quality controller or a nominated deputy. That removes a cost and a bottleneck you face in the EU. It does not remove the need for the certificate, the specification, the certificate of analysis or a proper technical agreement.

The fees themselves are small. Renewing a Home Office domestic licence costs £326 (CA$613), or £1,371 (CA$2,577) where a compliance visit is needed (GOV.UK). The money goes on the quality system behind the paperwork, not on the paperwork.

On price, recent trade data analysis put Q2 2026 landed values at about CA$2,289 per kg (£1,218) for the UK against CA$2,910 per kg (£1,548) for Germany. The UK pays less per kilo, but it is growing fast, and Canadian product already makes up more than half of what comes in.

Why it feels slower than it should

From the Canadian side, the UK can look like a simple sale that keeps stalling. There are usually four reasons.

  1. You are a line in someone else's licence. There is no UK application for you to make. Your product moves only when a UK importer puts their Home Office and MHRA permissions behind it, so their capacity and priorities set your pace.
  2. Two governments have to line up for every shipment. The Home Office issues the import licence first, and Health Canada issues the export permit against it. Both are time limited, so a slip on either side can send you back to the start.
  3. Nobody can market your product. Unlicensed medicines cannot be advertised in the UK, and prescribing is started by doctors on the GMC Specialist Register (MHRA). Demand comes from clinics choosing to stock and prescribe a product, which is a slower sale than a wholesale order.
  4. Continuity matters more than volume. A UK patient is prescribed a specific product. If the next batch is late or tests differently, the clinic has a problem and the importer remembers it. Smaller, regular, consistent shipments beat one large one.

None of this is a reason to stay away. It is a reason to choose your UK importer as carefully as they choose you, and to agree up front who owns the notification, the stability data, the artwork and the brand.

Why the certificate is not the business case

We have seen this film before. In early 2020 MJBizDaily reported that EU GMP had not been the revenue generator Canadian companies predicted. One producer had held its certificate for almost a year without disclosing any EU revenue.

The market is far bigger now, but the same risks are back in a different form.

  • Everyone is running at the same door. Wholesale flower in Canada has dropped below CA$1 per gram (about £0.53) in some categories, and exports escape the excise duty of CA$1 per gram or 10% of the selling price (MJBizDaily). Export looks like the answer to every producer at once, and prices follow.
  • Germany is carrying too much of the load. Canada supplied 93,006kg of Germany's 201 tonnes of imports in 2025, about 46%, and growth flattened in the final quarter (GrowerIQ). One analysis of Canadian trade data puts Germany at 56% of export value so far in 2026.
  • Policy can move faster than a validation programme. German proposals that would cut the amount of flower covered by health insurance, and growing European resistance to Canadian product on GMP grounds, both threaten the main pipeline (MJBizDaily).

A quick sense check on payback. Every £1m (CA$1.88m) you spend on GMP equals about 820kg of sales at the UK landed value above. That is revenue, not margin. If you do not know who is buying those kilos, and the several hundred after them, you do not have a business case yet.

What I would check before spending anything

  1. Name the buyer first. Get a signed offtake, or at least a committed importer, before design freeze. Your inspection will hang off an importer anyway, so find them early.
  2. Pay for a proper gap assessment. Measure the site against EudraLex Volume 4 and Annex 7 line by line. It tells you whether you are 6 months away or 2 years away, and it is the cheapest money in the whole programme.
  3. Fix the scope and the GMP boundary. Packing flower is a much smaller project than extraction and formulation, so choose and hold the line. Assume drying is inside GMP. Map every step from harvest to sealed pack and mark each one GACP or GMP, with the site that performs it.
  4. Start validation and stability on day one. These are the two programmes GPP sites rarely have, and stability cannot be hurried.
  5. Settle the decontamination question with your customer. Some Qualified Persons will not accept irradiated flower. Find out before you validate a process around it.
  6. Rehearse the inspection. Run a full mock audit with someone who has sat through a European one. Inspectors spend most of their time on records, deviations and CAPA, and on whether your people can explain their own procedures.
  7. Budget for the running cost. Lab fees, extra quality staff, requalification and reinspection carry on every year after the certificate arrives.
  8. Do not plan around one country. Germany and the UK have different rules, different prices and different risks. Build the dossier so it serves both.

None of this is an argument against EU GMP. For a Canadian producer who wants to sell medicine in Europe or the UK, there is no serious alternative. It is an argument for treating it as a commercial decision first and a quality project second.

If you are a Canadian producer weighing up the UK route and want a second opinion on the regulatory side, send me a message.

Reference materials

The standards

UK rules

Germany and the GMP boundary

Market data and costs

Cost estimates are published third party ranges, not quotes. Sterling and Canadian dollar figures are conversions at the rates stated above and will move with the market.